1286650

Fulvestrant

United States Pharmacopeia (USP) Reference Standard

• Synonim(y): (7α,17β)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol, Faslodex, ICI 182,780, ZD 182780, ZD 9238, ZM 182780
• Wzór empiryczny (zapis Hilla): C₃₂H₄₇F₅O₃S
• Numer CAS: 129453-61-8
• Masa cząsteczkowa: 606.77
• Numer MDL: MFCD00903953
• Kod UNSPSC: 41116107
• Identyfikator substancji w PubChem: 329749913
• NACRES: NA.24

Właściwości

• klasa czystości: pharmaceutical primary standard
• rodzina API: fulvestrant
• producent / nazwa handlowa: USP
• Zastosowanie: pharmaceutical (small molecule)
• format: neat
• temp. przechowywania: 2-8°C
• ciąg SMILES: [H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)Cc4cc(O)ccc24
• InChI: 1S/C32H47F5O3S/c1-30-17-15-26-25-12-11-24(38)21-23(25)20-22(29(26)27(30)13-14-28(30)39)10-7-5-3-2-4-6-8-18-41(40)19-9-16-31(33,34)32(35,36)37/h11-12,21-22,26-29,38-39H,2-10,13-20H2,1H3/t22-,26-,27+,28+,29-,30+,41?/m1/s1
• Klucz InChI: VWUXBMIQPBEWFH-WCCTWKNTSA-N
• informacje o genach: human ... ESR1(2099) , ESR2(2100)

Opis

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

• Targeted Radiation Drug for Breast Cancer: Fulvestrant was utilized in fluorocarbon nanoparticles combined with iodine-131, demonstrating potential as a targeted radiation drug for endocrine therapy in breast cancer treatment, enhancing the applicability of Fulvestrant in advanced therapeutic approaches (Zhi et al., 2024).


• Pharmacological Insights: A comprehensive review discussed novel oral selective estrogen receptor degraders, including Fulvestrant, detailing their mechanism and efficacy in breast cancer treatment, providing crucial insights for ongoing pharmaceutical research and development (Guglielmi et al., 2024).


• Quantification in Clinical Practice: Development of an LC-MS/MS method for the simultaneous quantification of four hormone therapy drugs, including Fulvestrant, in breast cancer patients supports its clinical application and monitoring, ensuring effective patient management and therapy optimization (Mansour et al., 2024).

Działania biochem./fizjol.

Fulvestrant (ICI 182,780) is a selective estrogen receptor down-regulator (SERD). Fulvestrant is a high affinity estrogen receptor antagonist. IC₅₀ = 0.29 nM. Fulvestrant is the first "pure" antiestrogen with no agonistic activity both in vitro and in vivo.

Komentarz do analizy

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Inne uwagi

Sales restrictions may apply.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS08,GHS09
• Hasło ostrzegawcze: Danger
• Zwroty wskazujące rodzaj zagrożenia: H360Df,H362,H410
• Zwroty wskazujące środki ostrożności: P202 - P260 - P263 - P264 - P273 - P308 + P313
• Klasyfikacja zagrożeń: Aquatic Chronic 1 - Lact. - Repr. 1B
• Kod klasy składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable